Dual GIP/GLP-1 receptor agonist with superior weight reduction outcomes vs semaglutide alone.
Pairs a GLP-1 receptor agonist with a long-acting amylin analogue. The two act on different satiety pathways, which is the rationale for combining them rather than raising the dose of either alone.
Active ingredient in Mounjaro and Zepbound. SURMOUNT-1 trial showed ~22% average body weight loss — significantly higher than semaglutide's ~15%.
The GIP component may contribute to improved tolerability, with some researchers reporting fewer GI side effects than pure GLP-1 agonists. GIP receptors are also expressed in bone and may have additional metabolic effects.